Trump Executive Order Fast-Tracks Psychedelic Therapies, Names Ibogaine for PTSD Despite Safety Concerns

What the Executive Order Means for Psychedelic Medicine

On April 18, 2026, President Donald Trump signed a far-reaching executive order that directs multiple federal agencies to fast-track the development, approval, and patient access to psychedelic therapies. The order explicitly names ibogaine—a compound derived from the roots of an African shrub—as a priority treatment for conditions like post-traumatic stress disorder (PTSD), depression, and substance use disorders. This move marks one of the most aggressive federal actions on psychedelic drugs in U.S. history and arrives amid a broader administration push that also includes reclassifying medical cannabis as a less dangerous substance.

The policy directly targets what the White House calls “the burden of suicide and serious mental illness rates in America,” with a special emphasis on veterans, who experience disproportionately high rates of PTSD, suicide, and traumatic brain injury. The order has been celebrated by psychedelic research organizations, veterans groups, and public figures such as podcaster Joe Rogan, whose personal advocacy helped catalyze the decision. However, the announcement has also raised serious questions among medical experts about whether the science can keep pace with the politics—particularly for ibogaine, which has a documented history of cardiotoxicity.

The Long Road from Counterculture to the White House

For decades, research into psychedelic therapies was largely frozen by the 1970 Controlled Substances Act, which classified substances like psilocybin, LSD, MDMA, and ibogaine as Schedule I drugs with no accepted medical use. That began to change in the early 2000s, when a small number of FDA-approved clinical trials revived scientific interest. Over the past 10 years, phase 2 and 3 studies have shown that psilocybin-assisted therapy can produce rapid and sustained reductions in depression and anxiety, often in patients who haven’t responded to standard treatments. MDMA-assisted therapy, meanwhile, has been studied extensively for PTSD and in 2023 received a Breakthrough Therapy designation from the FDA, putting it on an accelerated review track.

But ibogaine has lagged behind. While psilocybin and MDMA have each been through dozens of clinical trials involving hundreds of participants, ibogaine research remains sparse. Most human data come from observational studies, small case series, or underground treatment centers outside the U.S., particularly in Mexico. The substance is known to act on multiple receptor systems, including serotonin, opioid, and glutamate pathways, and unlike classical psychedelics, it produces an intense, often physically taxing experience that can last more than 24 hours. This has made it both a source of passionate advocacy and a focus of concern.

The Evidence: What the Research Actually Shows

The most compelling data cited by ibogaine proponents comes from a 2024 study conducted by Nolan R. Williams, MD, and colleagues at Stanford University, published in Nature Medicine. In that open-label case series, 30 U.S. combat veterans with traumatic brain injury (TBI) and severe psychiatric symptoms traveled to an ibogaine clinic in Mexico for treatment. The results were striking: one month after a single ibogaine session, the group’s average disability score plummeted from above 30 (indicating moderate-to-severe disability) to 5.1, a level that no longer qualified as disabled. Participants experienced an 88% reduction in PTSD symptoms, an 87% reduction in depression, and an 81% reduction in anxiety. No serious adverse events were reported during the study period.

However, the Stanford trial was small, lacked a control group, and relied on self-reported outcomes from a highly motivated sample. The researchers themselves called for randomized controlled trials to confirm the findings. This is not yet available. By comparison, phase 3 trials of MDMA-assisted therapy for PTSD—sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS)—have enrolled more than 200 participants across multiple sites and demonstrated a 67% response rate compared to 32% in the placebo group. Psilocybin therapy studies, such as a 2022 phase 2 trial published in The New England Journal of Medicine by Guy Goodwin and colleagues, showed that a single 25 mg dose led to a 57% remission rate in treatment-resistant depression at 3 weeks. Ibogaine has simply not reached that level of evidentiary rigor.

Safety data further complicate the picture. A 1993 FDA-approved clinical trial of ibogaine for opioid withdrawal had its funding rescinded after animal studies raised cardiac safety flags. Since then, case reports have documented multiple episodes of sudden cardiac death and cardiac arrest associated with ibogaine, even in otherwise healthy individuals. The mechanism of concern is QT interval prolongation—a disturbance in the heart’s electrical cycle that can trigger a potentially fatal arrhythmia called torsades de pointes. A 2016 review in the Journal of Forensic Sciences identified 19 ibogaine-related fatalities, and a 2025 case report in Cureus described a patient who suffered multiple cardiac arrests after ibogaine ingestion. Unlike psilocybin or MDMA, which have generally mild cardiovascular effects when used in controlled settings, ibogaine’s cardiac risks appear to be dose-dependent and unpredictable. The Stanford study did not report follow-up cardiac monitoring beyond the one-month mark.

What This Means for Patients and Families

If you or a loved one are struggling with PTSD, depression, or substance use disorder, the policy shift may feel like a long-awaited sign of hope—but it does not mean these treatments are ready for clinical use. The executive order directs the FDA to use Commissioner’s National Priority Vouchers to speed review times from six months to as few as one or two months for psychedelic therapies that have already earned Breakthrough Therapy designation. However, ibogaine has not received that designation. For patients, the order also points to the Right to Try Act, which would allow terminally ill individuals to access investigational drugs outside of clinical trials once basic safety requirements are met.

The bottom line is clear: no psychedelic therapy is yet FDA-approved for any mental health condition, and ibogaine in particular should never be used outside of a monitored medical setting with cardiac life support on standby. Traveling abroad for unregulated ibogaine treatment remains risky, and anyone considering it should be aware that no U.S. medical body endorses it at this stage. The $50 million allocated through ARPA-H to match state research grants will likely accelerate clinical trials, but real integration into psychiatric practice is still several years away.

Expert Perspective: Cautious Optimism Meets Stark Warnings

Matthew Johnson, PhD, professor of psychiatry and behavioral sciences at Johns Hopkins University, called the executive order “welcome news” and noted that it builds on “decades of science.” He acknowledged the special role that veteran advocates have played in pushing ibogaine forward, describing individuals who have “essentially made it their life’s mission” to help fellow veterans access the treatment. However, he also cautioned that ibogaine is at a “very different stage” compared to psilocybin and MDMA, largely because of the difficulty in securing research funding and regulatory approval for a substance with known safety concerns.

Richard Friedman, MD, psychiatrist and director of the Psychopharmacology Clinic at Weill Cornell Medicine, was more direct. “Ibogaine is probably the most dangerous of all psychedelic-like compounds,” he told Healthline. “It’s well known to have cardiotoxicity, which is not part of the public conversation, and that worries me.” Friedman emphasized that veterans need more than “a magic molecule”—they require comprehensive psychiatric care that includes empirically tested psychotherapies. He also stressed that it’s not yet clear whether ibogaine offers any distinct therapeutic advantage over safer psychedelics. “Anyone who knows anything about ibogaine would say pushing it as the first treatment to study is worrisome,” he said.

Frequently Asked Questions

Q: What does the executive order actually do?

The order directs the FDA to expedite the approval process for psychedelic therapies that have received Breakthrough Therapy designation, using priority review vouchers to shorten review timelines. It allocates $50 million through ARPA-H to match state funding for psychedelic research, mandates cross-agency collaboration to boost clinical trial participation, and explicitly recommends using the Right to Try Act to give eligible patients access to experimental psychedelic treatments. Additionally, it instructs the Attorney General to prepare for rescheduling certain psychedelics once Phase 3 trials are complete.

Q: Ibogaine is mentioned by name. What is it, and how does it differ from psilocybin or MDMA?

Ibogaine is a psychoactive compound extracted from the root bark of the Tabernanthe iboga shrub, native to Central Africa. Unlike classic psychedelics such as psilocybin and LSD, which primarily act on serotonin 2A receptors, ibogaine affects serotonin, opioid, and glutamate systems. Its effects can last over 24 hours and often include intense physical symptoms. Chemically and pharmacologically, it is not a traditional psychedelic but an atypical agent. Most importantly, it has a unique toxicity profile that includes potentially fatal QT interval prolongation, a cardiac risk not seen with psilocybin or MDMA in controlled medical settings.

Q: How strong is the evidence for ibogaine treating PTSD?

The strongest human data come from a 2024 Stanford University study of 30 combat veterans. That study reported large reductions in PTSD, depression, and anxiety symptoms one month after treatment, with no serious adverse events observed. However, the study was small, open-label, and lacked a control group; the researchers themselves stated that randomized controlled trials are needed. Ibogaine has not yet received FDA Breakthrough Therapy designation, unlike psilocybin and MDMA, which have been tested in much larger, more rigorous trials.

Q: Is it safe to try ibogaine at an underground clinic or abroad?

No. The documented cardiac risks—including QT prolongation, arrhythmias, and sudden cardiac arrest—make unsupervised ibogaine use extremely dangerous. Even in clinical settings, deaths have occurred. The FDA has not approved ibogaine for any medical use, and no professional medical organization endorses it. Anyone considering ibogaine should only do so within a registered clinical trial with continuous cardiac monitoring and emergency resuscitation capability. Psychedelic tourism to countries with looser regulations carries significant, potentially fatal risks.

Q: Will this order lead to psychedelics being legally available soon?

Not immediately. The order creates faster pathways for drugs that have already demonstrated substantial evidence of safety and efficacy in clinical trials. The Justice Department has been instructed to prepare to reschedule appropriate substances after Phase 3 trials succeed, but that process will likely take months to years. In the meantime, these compounds remain Schedule I substances under federal law, and possession remains a felony in most jurisdictions. The executive order is a policy signal, not a change in the legal status of any specific psychedelic drug.

Sources

• Williams NR et al. (2024). Ibogaine treatment for traumatic brain injury-related psychiatric symptoms in combat veterans: a case series. Nature Medicine. PMC10878970.
• White House. (2026). Accelerating Medical Treatments for Serious Mental Illness – Executive Order and Fact Sheet. Available at: whitehouse.gov.
• Friedman R, MD. Interview with Healthline, April 2026. Weill Cornell Medicine.
• Johnson M, PhD. Interview with Healthline, April 2026. Johns Hopkins University.
• Alper KR et al. (2008). The ibogaine medical subculture. Journal of Ethnopharmacology. (Cited in historical context; ibogaine safety data from multiple case reports as referenced in the main article.)
• Maas A et al. (2025). Multiple episodes of cardiac arrest induced by treatment with ibogaine: A case report. Cureus.
• Litjens RPW et al. (2016). Fatalities following ibogaine administration for opioid withdrawal: A forensic review. Journal of Forensic Sciences.